EUCTR2011-000765-12-DE进行中（未招募）不适用
Phase I/IIa study of immunization with frameshift peptides administered with Montanide ISA-51 VG in patients with advanced MSI-H colorectal cancer
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically confirmed, surgically resected colorectal cancer of advanced stage (UICC stage III/UICC stage IV). This comprises patients with lymph node metastases (UICC stage III), metastasis to one distant organ (UICC IV, M1a), to more than one distant organ, or patients with peritoneal carcinosis (M1b)
- •Detection of high level microsatellite instability (MSI-H) in the resected tumor sample according to the international consensus criteria (multiplex PCR of quasi-monomorphic microsatellite markers BAT25, BAT26, CAT25), see Appendix 1.
- •Prior adjuvant standard therapy (chemotherapy with 5-fluorouracil/folinic acid, oxaliplatin, irinotecan or combinations of these)
- •Prior palliative standard therapy in the first, second and third line (chemotherapy with 5-fluorouracil, oxaliplatin, irinotecan or combinations of these and/or treatment with anti-EGFR antibodies cetuximab or panitumumab alone or in combination with chemotherapy) with either complete or partial remission, stable disease, or disease progression under therapy;
- •Patient has refused adjuvant or palliative standard therapy (chemotherapy using 5-fluorouracil, oxaliplatin, or regimens combining these).
- •Expected survival of at least six months.
- •Full recovery from surgery or radiation therapy
- •ECOG performance status 0, 1 or 2.
- •The following laboratory results:
- •Neutrophil count> 1.5 x 109/L
- •Lymphocyte count > 0.5 x 109/L
- •Platelet count> 100 x 109/L
- •Serum bilirubin< 2mg/dL
- •Male or female patients = 18 years old
- •Last therapy discontinued at least 4 weeks prior to vaccination.
- •Patient´s written informed consent for participation in the trial
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 22
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 22
排除标准
- •Prior treatment with FSPs AIM2(-1), HT001(-1) and TAF1B(-1)
- •Clinically significant heart disease (NYHA Class IV).
- •Other serious illnesses, eg, serious infections requiring antibiotics or bleeding disorders.
- •History of immunodeficiency disease or autoimmune disease.
- •Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available.
- •HBV, HCV or HIV positivity.
- •Chemotherapy, any type of radiation therapy, or immunotherapy within 4 weeks before study entry
- •Concomitant treatment with steroids, antihistaminic drugs, or nonsteroidal anti-inflammatory drugs (unless used in low doses for prevention of an acute cardiovascular event or for pain control). Topical or inhalational steroids are permitted.
- •Participation in any other clinical trial
- •Pregnancy or lactation.
- •Women of childbearing potential who are not using a medically acceptable means of contraception. Appropriate contraception is defined as surgical sterilization (e.g., bilateral tubal ligation, vasectomy), hormonal contraception (implantable, patch, oral), and double-barrier methods (any double combination of: intrauterine device, male or female condom with spermicidal gel, diaphragm, sponge, cervical cap).
- •Psychiatric or addictive disorders that may compromise the ability to give informed consent.
- •Lack of availability of a patient for immunological and clinical follow-up assessment.
- •Brain metastases (symptomatic and non-symptomatic)
研究者
相似试验
进行中（未招募）
1 期
A Study of Safety and Clinical Activity of Cancer Immunotherapy Plus Chemotherapy in Metastatic Melanoma PatientsPatients with unresectable and progressive metastatic cutaneous melanoma, whose tumor expresses MAGE-A3.MedDRA version: 16.0Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2008-001918-25-BEGlaxoSmithKline Biologicals40
进行中（未招募）
1 期
A Study of Safety and Clinical Activity of Cancer Immunotherapy Plus Chemotherapy in Metastatic Melanoma PatientsEUCTR2008-001918-25-FRGlaxoSmithKline Biologicals48
进行中（未招募）
不适用
An open Phase II study of immunization with the recMAGE-A3 + AS01B Antigen-Specific Cancer Immunotherapeutic in patients with MAGE-A3-positive unresectable and progressive metastatic cutaneous melanoma. - MAGE3-AS01B-MEL-001 (MET)MAGE-A3-positive unresectable and progressive metastatic cutaneous melanoma.EUCTR2007-005203-18-GRGlaxoSmithKline Biologicals34
已完成
不适用
An open Phase I Study of immunization with the recNY-ESO-1 + AS15 Antigen-Specific Cancer Immunotherapeutic in patients with NY-ESO-1-positive unresectable and progressive metastatic cutaneous melanoma.skin cancer10040900melanomaNL-OMON41308GlaxoSmithKline6
进行中（未招募）
不适用
Randomized, open phase II study of immunization with the recombinant MAGE-3 protein combined with adjuvant AS02B or AS15 in patients with unresectable and progressive metastatic cutaneous melanoma.nresectable and progressive metastatic cutaneous melanomaMedDRA version: 9.1Level: LLTClassification code 10027480Term: Metastatic malignant melanomaEUCTR2004-001937-40-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER68